BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37728788)

  • 1. Biophysical Characterization of p51 and p66 Monomers of HIV-1 Reverse Transcriptase with Their Inhibitors.
    Seetaha S; Kamonsutthipaijit N; Yagi-Utsumi M; Seako Y; Yamaguchi T; Hannongbua S; Kato K; Choowongkomon K
    Protein J; 2023 Dec; 42(6):741-752. PubMed ID: 37728788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homodimerization of the p51 subunit of HIV-1 reverse transcriptase.
    Zheng X; Mueller GA; Cuneo MJ; Derose EF; London RE
    Biochemistry; 2010 Apr; 49(13):2821-33. PubMed ID: 20180596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative domain orientation of the L289K HIV-1 reverse transcriptase monomer.
    Xi Z; Ilina TV; Guerrero M; Fan L; Sluis-Cremer N; Wang YX; Ishima R
    Protein Sci; 2022 May; 31(5):e4307. PubMed ID: 35481647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
    Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
    Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
    Braz VA; Barkley MD; Jockusch RA; Wintrode PL
    Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms.
    Hsiou Y; Ding J; Das K; Clark AD; Hughes SH; Arnold E
    Structure; 1996 Jul; 4(7):853-60. PubMed ID: 8805568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site.
    Sharaf NG; Xi Z; Ishima R; Gronenborn AM
    Proteins; 2017 Dec; 85(12):2191-2197. PubMed ID: 28905420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Collective motions in HIV-1 reverse transcriptase: examination of flexibility and enzyme function.
    Bahar I; Erman B; Jernigan RL; Atilgan AR; Covell DG
    J Mol Biol; 1999 Jan; 285(3):1023-37. PubMed ID: 9887265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer.
    Wang J; Smerdon SJ; Jäger J; Kohlstaedt LA; Rice PA; Friedman JM; Steitz TA
    Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7242-6. PubMed ID: 7518928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
    Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
    J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subunit-specific analysis of the human immunodeficiency virus type 1 reverse transcriptase in vivo.
    Mulky A; Sarafianos SG; Arnold E; Wu X; Kappes JC
    J Virol; 2004 Jul; 78(13):7089-96. PubMed ID: 15194785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
    Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
    J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
    Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
    J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteolytic processing of an HIV-1 pol polyprotein precursor: insights into the mechanism of reverse transcriptase p66/p51 heterodimer formation.
    Sluis-Cremer N; Arion D; Abram ME; Parniak MA
    Int J Biochem Cell Biol; 2004 Sep; 36(9):1836-47. PubMed ID: 15183348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
    Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
    Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization.
    Tachedjian G; Aronson HE; de los Santos M; Seehra J; McCoy JM; Goff SP
    J Mol Biol; 2003 Feb; 326(2):381-96. PubMed ID: 12559908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spatial domain organization in the HIV-1 reverse transcriptase p66 homodimer precursor probed by double electron-electron resonance EPR.
    Schmidt T; Schwieters CD; Clore GM
    Proc Natl Acad Sci U S A; 2019 Sep; 116(36):17809-17816. PubMed ID: 31383767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase.
    Boyer PL; Ding J; Arnold E; Hughes SH
    Antimicrob Agents Chemother; 1994 Sep; 38(9):1909-14. PubMed ID: 7529011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
    Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
    FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Binding kinetics and affinities of heterodimeric versus homodimeric HIV-1 reverse transcriptase on DNA-DNA substrates at the single-molecule level.
    Marko RA; Liu HW; Ablenas CJ; Ehteshami M; Götte M; Cosa G
    J Phys Chem B; 2013 Apr; 117(16):4560-7. PubMed ID: 23305243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.